Target ALS and AFTD have announced $5 million in grants for research by six different teams to aid in the discovery of biomarkers and viable treatments for ALS and FTD, which overlap in genetic causes and biological mechanisms. Several of the teams who were awarded these grants include former AFTD grant recipients.

En unissant leurs forces, Target ALS et l'AFTD s'appuient sur l'expertise combinée de chercheurs dans deux domaines, alimentant la collaboration en faveur des idées les plus prometteuses. Ces projets nouvellement financés éclaireront et déboucheront potentiellement sur des traitements viables et sur les biomarqueurs indispensables pour permettre un diagnostic précis et mesurer la progression de la maladie.

“We’re proud to join Target ALS in announcing funding for these crucial funding efforts,” AFTD CEO Susan L-J Dickinson, MSGC, said. “With the challenges that the COVID-19 pandemic is adding for the families we serve, we want them to know that we are working as hard as ever to bring momentum for a day when treatments can halt FTD and ALS in their tracks.”

Cliquez ici for more information on the research partnership, including a brief overview of each funded award.